drugset / Trial / NCT05487859
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.
Timeline
- Start
- 2025-12-31
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acarbose | Unknown | 100 mg | Oral |